The clinical response to cancer therapies involves the complex interplay between the
systemic, tumoral, and stromal immune response as well as the direct impact of treatments …

Head and neck squamous cell carcinoma (HNSCC) accounts for more than 600,000 cases
and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)–associated …

Recent developments have renewed interest in understanding the interaction between
transformed cells and the immune system in the tumor microenvironment. Here, we provide …

Head and neck cancers are a heterogeneous group of tumors that are highly aggressive
and collectively represent the sixth most common cancer worldwide. Ninety percent of head …

The immune system plays a key role in the development, establishment, and progression of
head and neck squamous cell carcinoma (HNSCC). A greater understanding of the …

Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive solid tumor, with
a 5-year mortality rate of~ 50%. The development of immunotherapies has improved the …

The estimated annual incidence of oral cavity and pharyngeal cancer is 39,000 in the United
States and 260,000 cases worldwide. Despite significant advances in surgery …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Head-and-neck cancers constitute a heterogeneous group of aggressive tumors with high
incidence and low survival rates, collectively being the sixth most prevalent cancer type …

Head and neck cancers are still one of the most common types of cancer in the world. They
rank in the leading sixth place in terms of incidence globally, and the incidence continues to …